{
    "clinical_study": {
        "@rank": "19963", 
        "acronym": "RESTORE II", 
        "arm_group": {
            "arm_group_label": "ReZolve2 Treatment Group", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The RESTORE II clinical trial is intended to assess safety and performance of the ReZolve2\n      Bioresorbable Coronary Scaffold in native coronary arteries."
        }, 
        "brief_title": "ReZolve2 Clinical Investigation", 
        "completion_date": {
            "#text": "September 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Coronary Artery Disease", 
            "Coronary Artery Stenosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Coronary Stenosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Primary Inclusion Criteria:\n\n          -  Patient has evidence of myocardial ischemia or a positive functional study\n\n          -  Patient has a normal CK-MB\n\n          -  Target lesion has a visually estimated stenosis of \u226550% and <100%\n\n          -  Target lesion is located in a native coronary artery with average reference vessel\n             diameter \u2265 2.75mm and \u2264 3.3mm\n\n          -  Target lesion length must be \u2264 14mm\n\n        Primary Exclusion Criteria:\n\n          -  Patient has experienced a myocardial infarction (CK-MB or Troponin > 5 X ULN) within\n             72 hours of the procedure\n\n          -  Patient has a left ventricular ejection fraction < 30%\n\n          -  Patient has unprotected lest main coronary disease with \u226550% stenosis\n\n          -  The target vessel is totally occluded (TIMI Flow 0 or 1)\n\n          -  Target lesion involves a bifurcation (a lesion with a side branch \u2265 2.0 mm in\n             diameter containing a \u2265 50% stenosis).\n\n          -  Target lesion is located within a bypass graft\n\n          -  Target lesion has possible or definite thrombus"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "125", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01845311", 
            "org_study_id": "HCT4000"
        }, 
        "intervention": {
            "arm_group_label": "ReZolve2 Treatment Group", 
            "intervention_name": "ReZolve2 Scaffold", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Sydney", 
                        "country": "Australia"
                    }, 
                    "name": "St Vincent's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sao Paulo", 
                        "country": "Brazil"
                    }, 
                    "name": "Instituto Dante Pazzanese de Cariologia"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frankfurt", 
                        "country": "Germany"
                    }, 
                    "name": "Cardioangiologisches Centrum Bethanien"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Australia", 
                "Brazil", 
                "Germany"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "RESTORE II Trial: Safety & Performance Study of the ReZolve2 Sirolimus-Eluting Bioresorbable Coronary Scaffold", 
        "overall_official": [
            {
                "affiliation": "Instituto Dante Pazzanese de Cardiologia", 
                "last_name": "Alexandre Abizaid, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "St Vincent's Hospital, Sydney", 
                "last_name": "David Muller, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Australia: Australian Therapeutic Goods Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Major Adverse Cardiac Events (MACE)", 
                "safety_issue": "Yes", 
                "time_frame": "6 Months"
            }, 
            {
                "measure": "Major Adverse Cardiac Events", 
                "safety_issue": "Yes", 
                "time_frame": "12 Months"
            }, 
            {
                "measure": "Late Lumen Loss", 
                "safety_issue": "No", 
                "time_frame": "9 Months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01845311"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Late Loss, Restenosis Rate, % Diameter Stenosis & Minimum Lumen Diameter", 
                "measure": "QCA  derived parameters", 
                "safety_issue": "No", 
                "time_frame": "9 Months"
            }, 
            {
                "description": "Major Adverse Coronary Events - Combined events consisting of death, myocardial infarction and Target Lesion Revascularization", 
                "measure": "Major Adverse Coronary Events", 
                "safety_issue": "Yes", 
                "time_frame": "24, 36, 48 & 60 Months"
            }, 
            {
                "description": "Target Lesion Revascularization", 
                "measure": "TLR", 
                "safety_issue": "Yes", 
                "time_frame": "12,24,36,48 & 60 Months"
            }, 
            {
                "description": "Target Vessel Revascularization", 
                "measure": "TVR", 
                "safety_issue": "Yes", 
                "time_frame": "12,24,36,48 & 60 Months"
            }, 
            {
                "description": "Target Vessel Failure", 
                "measure": "TVF", 
                "safety_issue": "Yes", 
                "time_frame": "12, 24, 36, 48 & 60 Month"
            }, 
            {
                "description": "The percentage of patients meeting the Acute Technical Success criteria and the procedure results in a residual stenosis of <50 percent with no immediate (in-hospital) MACE.", 
                "measure": "Acute Procedural Success", 
                "safety_issue": "No", 
                "time_frame": "Day 0"
            }, 
            {
                "description": "The percentage of patients with successful delivery and deployment of the scaffold in the intended lesion without device related complications.", 
                "measure": "Acute Technical Success", 
                "safety_issue": "No", 
                "time_frame": "Day 0"
            }, 
            {
                "description": "The percentage of patients meeting the Acute Procedural Success criteria with no occurrence of a MACE event through 30 days.", 
                "measure": "Clinical Procedural Success", 
                "safety_issue": "No", 
                "time_frame": "30 Days"
            }
        ], 
        "source": "REVA Medical, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "REVA Medical, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}